These were predicted to be specific with high support for SCN5A in the heart (flecainide for prevention of arrhythmias), high support for PNLIP and strong support for LIPF in the small intestine and stomach, respectively (orlistat for reducing lipid uptake from the gut), strong support for TPO in the thyroid gland (methimazole for hyperthyroidism), strong support for SLC5A2 in kidney, medium support for CRP in the liver, high support for KLK3 in the prostate, and strong support for TNNT2 in the heart. This evidence concerns the gene TPO and hyperthyroidism.